Literature DB >> 34879993

SOHO State of the Art Updates and Next Questions: Treatment of Older, Vulnerable Adults with Multiple Myeloma.

Shakira J Grant1, Girija Joshi2, Brea Lipe3.   

Abstract

Multiple myeloma is primarily a disease of the elderly, and optimal treatments must weigh the risks of toxicity with the benefits of therapy.  Frailty scales have been developed to aid treatment-decision making for older adults with MM.   This review provides a framework for incorporating frailty scales into clinical care and highlights how patient-aligned priorities for care can influence the management of older or more vulnerable adults with newly diagnosed multiple myeloma newly diagnosed multiple myeloma. We review the currently available systemic therapies for managing older or more vulnerable adults with newly diagnosed multiple myeloma otherwise considered ineligible for autologous stem cell transplantation.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Mesh：

Year:  2021        PMID： 34879993      PMCID： PMC9050878          DOI： 10.1016/j.clml.2021.11.003

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


  42 in total

1.  Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.

Authors:  Peter M Voorhees; Jonathan L Kaufman; Jacob Laubach; Douglas W Sborov; Brandi Reeves; Cesar Rodriguez; Ajai Chari; Rebecca Silbermann; Luciano J Costa; Larry D Anderson; Nitya Nathwani; Nina Shah; Yvonne A Efebera; Sarah A Holstein; Caitlin Costello; Andrzej Jakubowiak; Tanya M Wildes; Robert Z Orlowski; Kenneth H Shain; Andrew J Cowan; Sean Murphy; Yana Lutska; Huiling Pei; Jon Ukropec; Jessica Vermeulen; Carla de Boer; Daniela Hoehn; Thomas S Lin; Paul G Richardson
Journal:  Blood       Date:  2020-08-20       Impact factor: 22.113

2.  Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline.

Authors:  Joseph Mikhael; Nofisat Ismaila; Matthew C Cheung; Caitlin Costello; Madhav V Dhodapkar; Shaji Kumar; Martha Lacy; Brea Lipe; Richard F Little; Anna Nikonova; James Omel; Namrata Peswani; Anca Prica; Noopur Raje; Rahul Seth; David H Vesole; Irwin Walker; Alexander Whitley; Tanya M Wildes; Sandy W Wong; Tom Martin
Journal:  J Clin Oncol       Date:  2019-04-01       Impact factor: 44.544

3.  Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

Authors:  Thierry Facon; Shaji Kumar; Torben Plesner; Robert Z Orlowski; Philippe Moreau; Nizar Bahlis; Supratik Basu; Hareth Nahi; Cyrille Hulin; Hang Quach; Hartmut Goldschmidt; Michael O'Dwyer; Aurore Perrot; Christopher P Venner; Katja Weisel; Joseph R Mace; Noopur Raje; Michel Attal; Mourad Tiab; Margaret Macro; Laurent Frenzel; Xavier Leleu; Tahamtan Ahmadi; Christopher Chiu; Jianping Wang; Rian Van Rampelbergh; Clarissa M Uhlar; Rachel Kobos; Ming Qi; Saad Z Usmani
Journal:  N Engl J Med       Date:  2019-05-30       Impact factor: 91.245

4.  Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

Authors:  Lotfi Benboubker; Meletios A Dimopoulos; Angela Dispenzieri; John Catalano; Andrew R Belch; Michele Cavo; Antonello Pinto; Katja Weisel; Heinz Ludwig; Nizar Bahlis; Anne Banos; Mourad Tiab; Michel Delforge; Jamie Cavenagh; Catarina Geraldes; Je-Jung Lee; Christine Chen; Albert Oriol; Javier de la Rubia; Lugui Qiu; Darrell J White; Daniel Binder; Kenneth Anderson; Jean-Paul Fermand; Philippe Moreau; Michel Attal; Robert Knight; Guang Chen; Jason Van Oostendorp; Christian Jacques; Annette Ervin-Haynes; Hervé Avet-Loiseau; Cyrille Hulin; Thierry Facon
Journal:  N Engl J Med       Date:  2014-09-04       Impact factor: 91.245

5.  Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.

Authors:  Hervé Avet-Loiseau; Cyrille Hulin; Loic Campion; Philippe Rodon; Gerald Marit; Michel Attal; Bruno Royer; Mamoun Dib; Laurent Voillat; Didier Bouscary; Denis Caillot; Marc Wetterwald; Brigitte Pegourie; Gerard Lepeu; Bernadette Corront; Lionel Karlin; Anne-Marie Stoppa; Jean-Gabriel Fuzibet; Xavier Delbrel; Francois Guilhot; Brigitte Kolb; Olivier Decaux; Thierry Lamy; Laurent Garderet; Olivier Allangba; Francois Lifermann; Bruno Anglaret; Philippe Moreau; Jean-Luc Harousseau; Thierry Facon
Journal:  J Clin Oncol       Date:  2013-06-24       Impact factor: 44.544

Review 6.  The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review.

Authors:  M E Hamaker; M C Prins; R Stauder
Journal:  Leuk Res       Date:  2013-12-30       Impact factor: 3.156

7.  Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.

Authors:  Maria-Victoria Mateos; Michele Cavo; Joan Blade; Meletios A Dimopoulos; Kenshi Suzuki; Andrzej Jakubowiak; Stefan Knop; Chantal Doyen; Paulo Lucio; Zsolt Nagy; Ludek Pour; Mark Cook; Sebastian Grosicki; Andre Crepaldi; Anna Marina Liberati; Philip Campbell; Tatiana Shelekhova; Sung-Soo Yoon; Genadi Iosava; Tomoaki Fujisaki; Mamta Garg; Maria Krevvata; Ying Chen; Jianping Wang; Anupa Kudva; Jon Ukropec; Susan Wroblewski; Ming Qi; Rachel Kobos; Jesus San-Miguel
Journal:  Lancet       Date:  2019-12-10       Impact factor: 79.321

8.  Geriatric-assessment-identified functional deficits among adults with multiple myeloma with normal performance status.

Authors:  Christopher E Jensen; Sanah N Vohra; Kirsten A Nyrop; Allison M Deal; Hyman B Muss; Eben I Lichtman; Samuel M Rubinstein; William A Wood; Nicholas J Mangieri; Lee Jamison; Shakira J Grant; Sascha A Tuchman
Journal:  J Geriatr Oncol       Date:  2021-08-11       Impact factor: 3.929

9.  Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis.

Authors:  Smith Giri; Alyssa Grimshaw; Susan Bal; Kelly Godby; Prakash Kharel; Benjamin Djulbegovic; Meletios A Dimopoulos; Thierry Facon; Saad Z Usmani; María-Victoria Mateos; Luciano J Costa
Journal:  JAMA Oncol       Date:  2020-11-01       Impact factor: 31.777

10.  Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).

Authors:  Robert Z Orlowski; Bart Barlogie; Brian G M Durie; Antje Hoering; Rachael Sexton; Muneer H Abidi; Joshua Epstein; S Vincent Rajkumar; Angela Dispenzieri; Stephen P Kahanic; Mohan C Thakuri; Frederic J Reu; Christopher M Reynolds
Journal:  Blood Cancer J       Date:  2020-05-11       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.